DUX1 Inhibitors
DUX1 inhibitors are a class of chemical compounds designed to modulate the activity of the Double Homeobox 1 (DUX1) protein, a transcription factor typically expressed in early embryonic development. DUX1 plays a significant role in gene regulation, particularly genes involved in the early stages of zygotic genome activation. However, aberrant expression of DUX1 outside of its normal developmental context can lead to dysregulation of gene networks and cellular pathways. This abnormal expression is particularly associated with specific cellular processes where DUX1 may disrupt normal function by altering transcriptional activity. As inhibitors of this protein, DUX1 inhibitors aim to prevent its ability to bind to DNA and initiate transcription, thereby controlling gene expression patterns associated with its activation.
These inhibitors typically work by binding to DUX1 or its DNA target sites, blocking its interaction with genomic sequences, or interfering with the downstream pathways regulated by DUX1. The structural diversity of DUX1 inhibitors can range from small organic molecules to larger macromolecular structures designed to target the protein-DNA interface or its co-factors. By impeding DUX1 activity, these compounds can effectively modify gene expression, cellular phenotype, and even protein production in cells where DUX1 expression is dysregulated. The chemistry of DUX1 inhibitors is highly specialized and focuses on enhancing their specificity and binding affinity to DUX1 or its associated molecular components, while minimizing off-target interactions to ensure precise modulation of this transcription factor. The development of such inhibitors contributes to a deeper understanding of gene regulation mechanisms and how transcription factors like DUX1 can be selectively targeted at the molecular level.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A could condense chromatin structure around the DUX1 gene locus by preventing histone deacetylation, thereby hindering the transcriptional machinery's access to the gene and downregulating DUX1 expression. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This compound could decrease the methylation levels of the DUX1 promoter region, which might inadvertently lead to the silencing of DUX1 expression due to changes in chromatin conformation and DNA accessibility. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
By binding to and inhibiting RNA polymerase II, α-Amanitin could directly block the transcriptional elongation of the DUX1 gene, leading to a significant decrease in DUX1 mRNA synthesis. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D can intercalate into DNA and obstruct the advancement of RNA polymerase along the DUX1 gene, which would result in a decrease in the overall transcriptional activity of DUX1. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mTOR pathway, which is crucial for cap-dependent mRNA translation; this could indirectly lead to reduced translation of DUX1 mRNA into protein, effectively decreasing DUX1 expression at the post-transcriptional level. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
5-Aza-2′-Deoxycytidine might reduce the methylation of cytosine residues within the DUX1 promoter, potentially leading to an unexpected transcriptional repression of the DUX1 gene through alteration of transcription factor binding profiles. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib could stabilize cellular proteins that normally degrade transcription factors or other proteins that promote DUX1 expression, thereby indirectly reducing the levels of DUX1 through decreased transcriptional activation. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1 binds to BET bromodomains, potentially displacing transcriptional coactivators from chromatin; this could lead to a decreased recruitment of transcriptional machinery to the DUX1 gene and subsequent downregulation of its expression. | ||||||
Pladienolide B | 445493-23-2 | sc-391691 sc-391691B sc-391691A sc-391691C sc-391691D sc-391691E | 0.5 mg 10 mg 20 mg 50 mg 100 mg 5 mg | $299.00 $5699.00 $11099.00 $25500.00 $66300.00 $2875.00 | 63 | |
By targeting the spliceosome, Pladienolide B could disrupt the normal splicing of DUX1 pre-mRNA, potentially leading to the production of non-functional DUX1 mRNA variants and a reduction in functional DUX1 protein. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol inhibits CDK9, a key component of the P-TEFb complex involved in mRNA elongation; inhibition could hinder the progression of RNA polymerase II along the DUX1 gene, leading to decreased mRNA production. | ||||||